仙琚製藥(002332.SZ):適當佈局診斷檢測領域 擬與清華大學等設梓晶生物
格隆匯 3 月 18日丨仙琚製藥(002332.SZ)公佈,為有效承接外部研發資源,適當佈局診斷檢測領域。公司擬出資1960.73萬元與清華大學、全芯集力(寧波)生物技術合夥企業(有限合夥)共同投資設立“杭州梓晶生物科技有限公司”(具體以工商核准的名稱為準,“梓晶生物”)。
擬參股公司註冊資本500萬元,公司擬以自有資金現金出資1960.73萬元,認繳註冊資本245萬元,佔註冊資本49%;清華大學擬以其專有知識產權技術評估作價出資1940.72萬元,認繳註冊資本242.5萬元,佔註冊資本48.50%;全芯集力(寧波)生物技術合夥企業(有限合夥)以自有資金現金出資100.55萬元,認繳註冊資本12.5萬元,佔註冊資本2.50%。
此次與清華大學共同投資設立合資公司,主要為有效承接外部研發資源,在原有基礎上加深合作,公司適當佈局診斷和檢測領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.